Clinical Trials Logo

Clinical Trial Summary

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Breast Neoplasms
  • Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

NCT number NCT04546009
Study type Interventional
Source Hoffmann-La Roche
Status Active, not recruiting
Phase Phase 3
Start date October 9, 2020
Completion date March 18, 2027